The role of biomarker in later-line treatment for metastatic colorectal cancer.
作者信息
Kawakami Takeshi, Yamazaki Kentaro
机构信息
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
出版信息
J Gastrointest Oncol. 2023 Apr 29;14(2):1178-1180. doi: 10.21037/jgo-2023-01. Epub 2023 Mar 24.
Abstract
摘要
相似文献
1
The role of biomarker in later-line treatment for metastatic colorectal cancer.生物标志物在转移性结直肠癌后线治疗中的作用。
J Gastrointest Oncol. 2023 Apr 29;14(2):1178-1180. doi: 10.21037/jgo-2023-01. Epub 2023 Mar 24.
2
Prognostic Significance of the C-Reactive Protein-to-Albumin Ratio in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Thymidine Phosphorylase Inhibitor as Later-line Chemotherapy.三氟尿苷/胸苷磷酸化酶抑制剂作为晚期化疗药物治疗转移性结直肠癌患者时C反应蛋白与白蛋白比值的预后意义
Anticancer Res. 2019 Feb;39(2):1051-1057. doi: 10.21873/anticanres.13212.
3
Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.EFFORT 研究方案：在不可切除/转移性结直肠癌患者中，FOLFOXIRI 联合贝伐珠单抗治疗进展后或维持治疗期间使用 FOLFIRI 联合阿柏西普二线治疗的前瞻性研究。
BMC Cancer. 2020 Nov 17;20(1):1116. doi: 10.1186/s12885-020-07576-9.
4
Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.接受西妥昔单抗治疗转移性结直肠癌的后续疗程患者的真实世界总生存期
Future Oncol. 2022 Sep;18(29):3299-3310. doi: 10.2217/fon-2022-0432. Epub 2022 Sep 6.
5
Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.提高晚期非小细胞肺癌和转移性结直肠癌的生物标志物检测水平：来自美国大型社区肿瘤学网络的经验。
Future Oncol. 2023 Jun;19(20):1397-1414. doi: 10.2217/fon-2022-1216. Epub 2023 Jun 15.
6
and Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study.并发性结直肠癌标准化学疗法反应的预后和预测生物标志物：单机构研究。
Cells. 2020 Jan 15;9(1):219. doi: 10.3390/cells9010219.
7
Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study.原发性肿瘤位置对转移性结直肠癌患者抗表皮生长因子受体抗体二线或后续治疗的影响：一项回顾性多中心研究
Front Oncol. 2022 Feb 15;12:813009. doi: 10.3389/fonc.2022.813009. eCollection 2022.
8
Spotlight on panitumumab in metastatic colorectal cancer.重点关注转移性结直肠癌的 panitumumab。
BioDrugs. 2010 Aug 1;24(4):275-8. doi: 10.2165/11205460-000000000-00000.
9
Panitumumab: a review of its use in metastatic colorectal cancer.帕尼单抗：在转移性结直肠癌中的应用评价。
Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000.
10
Time-varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population-based study and meta-analysis.原发肿瘤侧别在转移性结直肠癌中的时变预后价值：基于人群的研究和荟萃分析。
Int J Cancer. 2023 Apr 1;152(7):1360-1369. doi: 10.1002/ijc.34347. Epub 2022 Nov 30.
引用本文的文献
1
An unusual presentation of solitary ovarian metastasis from colorectal cancer in an elderly woman: a case report.一名老年女性结直肠癌孤立性卵巢转移的罕见表现：病例报告
J Gastrointest Oncol. 2024 Jun 30;15(3):1309-1314. doi: 10.21037/jgo-24-411. Epub 2024 Jun 27.
本文引用的文献
1
Effectiveness, safety, and prognostic factors of trifluridine/tipiracil for the treatment of patients with metastatic colorectal cancer in routine clinical practice.曲氟尿苷/替匹嘧啶在常规临床实践中治疗转移性结直肠癌患者的有效性、安全性及预后因素
J Gastrointest Oncol. 2023 Apr 29;14(2):692-704. doi: 10.21037/jgo-22-517. Epub 2023 Feb 24.
2
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.转移性结直肠癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25.
3
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.KRAS 密码子 12 或 13 突变对预处理转移性结直肠癌患者接受曲氟尿苷/替匹嘧啶治疗的生存影响：一项荟萃分析。
ESMO Open. 2022 Jun;7(3):100511. doi: 10.1016/j.esmoop.2022.100511. Epub 2022 Jun 7.
4
The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study.增加转移性结直肠癌活性药物数量的生存获益：一项多中心回顾性研究。
Cancer Med. 2022 Jun;11(11):2184-2192. doi: 10.1002/cam4.4599. Epub 2022 Feb 19.
5
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer.泛亚地区适应的 ESMO 临床实践指南：局部结肠癌的诊断、治疗和随访。
Ann Oncol. 2021 Dec;32(12):1496-1510. doi: 10.1016/j.annonc.2021.08.1752. Epub 2021 Aug 16.
6
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.FRESCO-2：一项全球性 III 期研究，旨在评估 fruquintinib 治疗转移性结直肠癌的疗效和安全性。
Future Oncol. 2021 Aug;17(24):3151-3162. doi: 10.2217/fon-2021-0202. Epub 2021 May 17.
7
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.RAS 突变状态指导下接受标准治疗失败的转移性结直肠癌患者接受替氟尿苷/盐酸拓扑替康联合贝伐珠单抗治疗的 II 期研究：JFMC51-1702-C7。
ESMO Open. 2021 Apr;6(2):100093. doi: 10.1016/j.esmoop.2021.100093. Epub 2021 Mar 19.
8
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.结肠癌临床实践指南（2021 年第 2 版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Mar 2;19(3):329-359. doi: 10.6004/jnccn.2021.0012.
9
Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.替氟尿苷/盐酸拓扑替康联合贝伐珠单抗三线治疗转移性结直肠癌的研究：SUNLIGHT 研究设计。
Future Oncol. 2021 Jun;17(16):1977-1985. doi: 10.2217/fon-2020-1238. Epub 2021 Feb 11.
10
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).双周给药TAS-102联合贝伐单抗治疗标准疗法难治性转移性结直肠癌的Ib/II期研究（BiTS研究）
Oncologist. 2020 Dec;25(12):e1855-e1863. doi: 10.1634/theoncologist.2020-0643. Epub 2020 Aug 3.
Zotero 插件